FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2755446979> ?p ?o ?g. }

• W2755446979 abstract "Surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in Europe is performed through the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), which additionally provides data to inform the European gonorrhoea treatment guideline; currently recommending ceftriaxone 500 mg plus azithromycin 2 g as first-line therapy. We present antimicrobial susceptibility data from 24 European countries in 2015, linked to epidemiological data of patients, and compare the results to Euro-GASP data from previous years. Antimicrobial susceptibility testing by MIC gradient strips or agar dilution methodology was performed on 2134 N. gonorrhoeae isolates and interpreted using EUCAST breakpoints. Patient variables associated with resistance were established using logistic regression to estimate odds ratios (ORs). In 2015, 1.7% of isolates were cefixime resistant compared to 2.0% in 2014. Ceftriaxone resistance was detected in only one (0.05%) isolate in 2015, compared with five (0.2%) in 2014. Azithromycin resistance was detected in 7.1% of isolates in 2015 (7.9% in 2014), and five (0.2%) isolates displayed high-level azithromycin resistance (MIC ≥ 256 mg/L) compared with one (0.05%) in 2014. Ciprofloxacin resistance remained high (49.4%, vs. 50.7% in 2014). Cefixime resistance significantly increased among heterosexual males (4.1% vs. 1.7% in 2014), which was mainly attributable to data from two countries with high cefixime resistance (~11%), however rates among men-who-have-sex-with-men (MSM) and females continued to decline to 0.5% and 1%, respectively. Azithromycin resistance in MSM and heterosexual males was higher (both 8.1%) than in females (4.9% vs. 2.2% in 2014). The association between azithromycin resistance and previous gonorrhoea infection, observed in 2014, continued in 2015 (OR 2.1, CI 1.2–3.5, p < 0.01). The 2015 Euro-GASP sentinel system revealed high, but stable azithromycin resistance and low overall resistance to ceftriaxone and cefixime. The low cephalosporin resistance may be attributable to the effectiveness of the currently recommended first-line dual antimicrobial therapy; however the high azithromycin resistance threatens the effectiveness of this therapeutic regimen. Whether the global use of azithromycin in mono- or dual antimicrobial therapy of gonorrhoea is contributing to the global increases in azithromycin resistance remains to be elucidated. The increasing cefixime resistance in heterosexual males also needs close monitoring." @default.
• W2755446979 created "2017-09-25" @default.
• W2755446979 creator A5000013450 @default.
• W2755446979 creator A5003229644 @default.
• W2755446979 creator A5056363494 @default.
• W2755446979 creator A5067099903 @default.
• W2755446979 creator A5069892567 @default.
• W2755446979 creator A5072141437 @default.
• W2755446979 creator A5087029001 @default.
• W2755446979 date "2017-09-11" @default.
• W2755446979 modified "2023-10-09" @default.
• W2755446979 title "Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015" @default.
• W2755446979 cites W1967593111 @default.
• W2755446979 cites W1986274110 @default.
• W2755446979 cites W1991435114 @default.
• W2755446979 cites W1999596396 @default.
• W2755446979 cites W2032241110 @default.
• W2755446979 cites W2081475323 @default.
• W2755446979 cites W2098195349 @default.
• W2755446979 cites W2101812185 @default.
• W2755446979 cites W2102338246 @default.
• W2755446979 cites W2147292570 @default.
• W2755446979 cites W2159869976 @default.
• W2755446979 cites W2168016331 @default.
• W2755446979 cites W2201314748 @default.
• W2755446979 cites W2203537645 @default.
• W2755446979 cites W2231652168 @default.
• W2755446979 cites W2339666879 @default.
• W2755446979 cites W2341783622 @default.
• W2755446979 cites W2413072555 @default.
• W2755446979 cites W2416229675 @default.
• W2755446979 cites W2462093517 @default.
• W2755446979 cites W2464932009 @default.
• W2755446979 cites W2501329550 @default.
• W2755446979 cites W2599437121 @default.
• W2755446979 cites W2915737634 @default.
• W2755446979 cites W2917241477 @default.
• W2755446979 cites W34855022 @default.
• W2755446979 doi "https://doi.org/10.1186/s12879-017-2707-z" @default.
• W2755446979 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5594611" @default.
• W2755446979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28893203" @default.
• W2755446979 hasPublicationYear "2017" @default.
• W2755446979 type Work @default.
• W2755446979 sameAs 2755446979 @default.
• W2755446979 citedByCount "87" @default.
• W2755446979 countsByYear W27554469792017 @default.
• W2755446979 countsByYear W27554469792018 @default.
• W2755446979 countsByYear W27554469792019 @default.
• W2755446979 countsByYear W27554469792020 @default.
• W2755446979 countsByYear W27554469792021 @default.
• W2755446979 countsByYear W27554469792022 @default.
• W2755446979 countsByYear W27554469792023 @default.
• W2755446979 crossrefType "journal-article" @default.
• W2755446979 hasAuthorship W2755446979A5000013450 @default.
• W2755446979 hasAuthorship W2755446979A5003229644 @default.
• W2755446979 hasAuthorship W2755446979A5056363494 @default.
• W2755446979 hasAuthorship W2755446979A5067099903 @default.
• W2755446979 hasAuthorship W2755446979A5069892567 @default.
• W2755446979 hasAuthorship W2755446979A5072141437 @default.
• W2755446979 hasAuthorship W2755446979A5087029001 @default.
• W2755446979 hasBestOaLocation W27554469791 @default.
• W2755446979 hasConcept C114851261 @default.
• W2755446979 hasConcept C126322002 @default.
• W2755446979 hasConcept C159047783 @default.
• W2755446979 hasConcept C176947019 @default.
• W2755446979 hasConcept C190139176 @default.
• W2755446979 hasConcept C2776520383 @default.
• W2755446979 hasConcept C2778243283 @default.
• W2755446979 hasConcept C2778512257 @default.
• W2755446979 hasConcept C2778907293 @default.
• W2755446979 hasConcept C2779166590 @default.
• W2755446979 hasConcept C2780493024 @default.
• W2755446979 hasConcept C42972112 @default.
• W2755446979 hasConcept C4937899 @default.
• W2755446979 hasConcept C501593827 @default.
• W2755446979 hasConcept C71924100 @default.
• W2755446979 hasConcept C81396022 @default.
• W2755446979 hasConcept C86803240 @default.
• W2755446979 hasConcept C89423630 @default.
• W2755446979 hasConcept C94665300 @default.
• W2755446979 hasConceptScore W2755446979C114851261 @default.
• W2755446979 hasConceptScore W2755446979C126322002 @default.
• W2755446979 hasConceptScore W2755446979C159047783 @default.
• W2755446979 hasConceptScore W2755446979C176947019 @default.
• W2755446979 hasConceptScore W2755446979C190139176 @default.
• W2755446979 hasConceptScore W2755446979C2776520383 @default.
• W2755446979 hasConceptScore W2755446979C2778243283 @default.
• W2755446979 hasConceptScore W2755446979C2778512257 @default.
• W2755446979 hasConceptScore W2755446979C2778907293 @default.
• W2755446979 hasConceptScore W2755446979C2779166590 @default.
• W2755446979 hasConceptScore W2755446979C2780493024 @default.
• W2755446979 hasConceptScore W2755446979C42972112 @default.
• W2755446979 hasConceptScore W2755446979C4937899 @default.
• W2755446979 hasConceptScore W2755446979C501593827 @default.
• W2755446979 hasConceptScore W2755446979C71924100 @default.
• W2755446979 hasConceptScore W2755446979C81396022 @default.
• W2755446979 hasConceptScore W2755446979C86803240 @default.
• W2755446979 hasConceptScore W2755446979C89423630 @default.
• W2755446979 hasConceptScore W2755446979C94665300 @default.
• W2755446979 hasFunder F4320320304 @default.

• next